News Tarsus gets first FDA nod for mite blepharitis therapy A common eyelid disease caused by infestation with tiny parasitic mites that live in hair follicles now has its first approved treatment in the US.<
News Lilly weakens on oral weight-loss drug data Shares in Eli Lilly have come under pressure after reporting the results of a phase 3 trial of oral weight-loss candidate orforglipron.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face